Skip to main content

Cancer: Children

Question for Department of Health and Social Care

UIN 96063, tabled on 28 September 2020

To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of the treatment options available on the NHS for children with diffuse midline glioma; and whether he plans to improve those treatment options.

This answer is the replacement for a previous holding answer.

Answered on

22 October 2020

The National Institute for Health and Care Excellence (NICE) has not made an assessment of any treatments for children with diffuse midline glioma.

However, NICE is planning to develop guidance on MTX110 for untreated diffuse intrinsic pontine glioma (DIPG), also known as diffuse midline glinoma. The timescale for this will be announced in due course.

NICE is also aware of a further drug, tasadenoturev (DNX-2401) for DIPG, that is currently undergoing clinical trials. If successful, NICE will appraise this drug once it has been licensed.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.